NCT02231164 - LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2014

Primary Completion Date

December 24, 2015

Study Completion Date

December 24, 2015

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

docetaxel

intravenous chemotherapy drug

DRUG

docetaxel

intravenous chemotherapy drug

DRUG

placebo

oral placebo

DRUG

nintedanib

oral experimental therapy

Trial Locations (13)

1199.128.10032 Boehringer Ingelheim Investigational Site, Chandler

1199.128.10041 Boehringer Ingelheim Investigational Site, Fayetteville

1199.128.10010 Boehringer Ingelheim Investigational Site, Highland

1199.128.10044 Boehringer Ingelheim Investigational Site, Rancho Mirage

1199.128.10080 Boehringer Ingelheim Investigational Site, Paducah

1199.128.10016 Boehringer Ingelheim Investigational Site, Farmington

1199.128.10013 Boehringer Ingelheim Investigational Site, Minot

1199.128.10077 Boehringer Ingelheim Investigational Site, Blacksburg

1199.128.10011 Boehringer Ingelheim Investigational Site, Kennewick

1199.128.64006 Boehringer Ingelheim Investigational Site, Batumi

1199.128.64001 Boehringer Ingelheim Investigational Site, Tbilisi

1199.128.64002 Boehringer Ingelheim Investigational Site, Tbilisi

1199.128.66004 Boehringer Ingelheim Investigational Site, Bangkok